FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3598-3605

  Kadota, Kyuichi ^a,b   Colovos, Christos ^a   Suzuki, Kei ^a   Rizk, Nabil P ^a   Dunphy, Mark P S ^a   Zabor, Emily C ^a   Sima, Camelia S ^a   Yoshizawa, Akihiko ^c   Travis, William D ^a   Rusch, Valerie W ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; AMERICAN THORACIC SOCIETY CLASSIFICATION; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DRUG UPTAKE; EUROPEAN RESPIRATORY SOCIETY CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER CLASSIFICATION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84868205889     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2414-3     Document Type: Article

References (30)

1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2: 706-14. (Pubitemid 47357522)
2. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6: 244-85.
3. Yoshizawa A, Sumiyoshi S, Moreira AL, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification and use of comprehensive histologic subtyping for architectural grading in 432 Japanese patients. Mod Pathol. 2011;24:429A.
4. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24:653-64.
5. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010; 34:1155-62.
6. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6: 3837-44.
7. Takenaka T, Yano T, Ito K, et al. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer. J Surg Oncol. 2009; 100:688-92.
8. Nakamura H, Hirata T, Kitamura H, et al. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg. 2009;15:304-10.
9. Ohtsuka T, Nomori H, Watanabe K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006;107:2468-73. (Pubitemid 44748531)
10. Nakayama H, Okumura S, Daisaki H, et al. Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: A multicenter study. Cancer. 2010;116:3170-7.
11. Shiono S, Abiko M, Sato T. Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers. J Thorac Oncol. 2011;6: 43-47.
12. Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol. 2008;3:130-4. (Pubitemid 351323186)
13. Nair VS, Barnett PG, Ananth L, et al. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest. 2010;137:1150-6.
14. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-60. (Pubitemid 41103680)
15. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res. 2007;13:3255-63. (Pubitemid 46944910)
16. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: Analysis of 176 cases. Eur J Cardiothorac Surg. 2008;34:892-7.
17. Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151-9. (Pubitemid 40941684)
18. Vesselle H, Salskov A, Turcotte E, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971-8.
19. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92. (Pubitemid 30046688)
20. Sawada E, Nambu A, Motosugi U, et al. Localized mucinous bronchioloalveolar carcinoma of the lung: Thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. Jpn J Radiol. 2010;28:251-8.
21. Shim SS, Han J. FDG-PET/CT imaging in assessing mucinproducing non-small cell lung cancer with pathologic correlation. Ann Nucl Med. 2010;24:357-62.
22. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2009. p. 253-70.
23. Thomas JS, Kerr GR, Jack WJ, et al. Histological grading of invasive breast carcinoma - a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology. 2009;55:724-31.
24. Asamura H, Ando M, Matsuno Y, et al. Histopathologic prognostic factors in resected adenocarcinomas: Is nuclear DNA content prognostic? Chest. 1999;115:1018-24. (Pubitemid 29193672)
25. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010;116:659-69.
26. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-44. (Pubitemid 28364493)
27. Baak JP. Mitosis counting in tumors. Hum Pathol. 1990;21: 683-5. (Pubitemid 20216807)
28. Kadota K, Suzuki K, Rusch VW, et al. Nuclear grading system predicts recurrence in stage I lung adenocarcinoma patients. Mod Pathol. 2011;24:413A.
29. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-54.
30. Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-8. (Pubitemid 351583988)